AVEO

AVEO is a biopharmaceutical company focused on oncology, dedicated to delivering medicines that provide a better life for cancer patients. AVEO's lead candidate drug, FOTIVDA® (tivozanib), was approved by the U.S. Food and Drug Administration (FDA) on March 10, 2021, for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) who have received two or more prior systemic therapies.